Jazz Pharmaceuticals (JAZZ) Accumulated Expenses (2010 - 2026)

Jazz Pharmaceuticals has reported Accumulated Expenses for 17 years, with the latest figure at $1.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 3.9% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2026 stood at $1.0 billion (down 3.9% YoY), and the FY2025 full-year result was $1.0 billion, up 13.53% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $1.0 billion, down from $1.0 billion in the prior quarter.
• The five-year high for Accumulated Expenses was $1.1 billion in Q1 2025, with the low at $593.2 million in Q2 2022.
• Average Accumulated Expenses over 5 years is $828.7 million, with a median of $803.3 million recorded in 2022.
• Year-over-year, Accumulated Expenses jumped 61.67% in 2022 and slipped 3.9% in 2026.
• Tracing JAZZ's Accumulated Expenses over 5 years: stood at $803.3 million in 2022, then fell by 1.16% to $793.9 million in 2023, then climbed by 14.74% to $910.9 million in 2024, then increased by 13.53% to $1.0 billion in 2025, then retreated by 1.14% to $1.0 billion in 2026.
• The last three Accumulated Expenses figures came in at $1.0 billion (Q1 2026), $1.0 billion (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.

Peer Comparison